share_log

Argus Research Initiates Coverage On Novo Nordisk With Buy Rating, Announces Price Target of $110

Benzinga ·  Oct 2, 2023 10:30

Argus Research analyst John Eade initiates coverage on Novo Nordisk (NYSE:NVO) with a Buy rating and announces Price Target of $110.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment